Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.
暂无分享,去创建一个
A. Schetter | D. Lowy | Xi Liu | A. Robles | W. Vass | A. Papageorge | Aaron J. Schetter | X. Qian | Xiaoli Du | R. Braverman
[1] B. J. Clark,et al. The mammalian START domain protein family in lipid transport in health and disease. , 2012, The Journal of endocrinology.
[2] I. Ng,et al. Caveolin‐1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis , 2012, The Journal of pathology.
[3] D. Lowy,et al. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK) , 2011, Proceedings of the National Academy of Sciences.
[4] Keith Burridge,et al. The 'invisible hand': regulation of RHO GTPases by RHOGDIs , 2011, Nature Reviews Molecular Cell Biology.
[5] D. Zimonjic,et al. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. , 2011, Cancer research.
[6] J. Cherfils,et al. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? , 2010, Nature Reviews Cancer.
[7] L. Giménez,et al. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer , 2010, Journal of Translational Medicine.
[8] L. Diao,et al. Caveolin-1 and VEGF-C promote Lymph Node Metastasis in the Absence of Intratumoral Lymphangiogenesis in Non-small Cell Lung Cancer , 2010, Tumori.
[9] M. Shatz,et al. Caveolin-1 mutants P132L and Y14F are dominant negative regulators of invasion, migration and aggregation in H1299 lung cancer cells. , 2010, Experimental cell research.
[10] H. Sugimoto,et al. StarD7 Mediates the Intracellular Trafficking of Phosphatidylcholine to Mitochondria* , 2009, The Journal of Biological Chemistry.
[11] R. Karlsson,et al. Rho GTPase function in tumorigenesis. , 2009, Biochimica et biophysica acta.
[12] D. Lowy,et al. The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. , 2009, Cancer cell.
[13] I. Ng,et al. Deleted in Liver Cancer 1 (DLC1) Utilizes a Novel Binding Site for Tensin2 PTB Domain Interaction and Is Required for Tumor-Suppressive Function , 2009, PloS one.
[14] D. Lowy,et al. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities , 2009, Oncogene.
[15] C. Der,et al. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility , 2009, Cancer and Metastasis Reviews.
[16] Boon Chuan Low,et al. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration , 2009, Journal of Cell Science.
[17] Monilola A. Olayioye,et al. Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. , 2008, Cancer research.
[18] T. Godfrey,et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer , 2008, Nucleic acids research.
[19] A. Tonevitsky,et al. Differences in gene expression levels between early and later stages of human lung development are opposite to those between normal lung tissue and non-small lung cell carcinoma. , 2008, Lung cancer.
[20] S. Lo,et al. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. , 2008, Cancer research.
[21] Igor Jurisica,et al. Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.
[22] S. Wiseman,et al. Caveolin-1 in tumor progression: the good, the bad and the ugly , 2008, Cancer and Metastasis Reviews.
[23] John G. Collard,et al. Rho GTPases: functions and association with cancer , 2007, Clinical & Experimental Metastasis.
[24] C. Ukomadu,et al. Interacting Proteins Dictate Function of the Minimal START Domain Phosphatidylcholine Transfer Protein/StarD2* , 2007, Journal of Biological Chemistry.
[25] Douglas R Lowy,et al. DLC-1:a Rho GTPase-activating protein and tumour suppressor , 2007, Journal of cellular and molecular medicine.
[26] M. Guan,et al. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth , 2007, Oncogene.
[27] Kenneth M. Yamada,et al. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities , 2007, Proceedings of the National Academy of Sciences.
[28] S. Lo,et al. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1 , 2007, The Journal of cell biology.
[29] I. Ng,et al. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. , 2006, Cancer research.
[30] I. Ng,et al. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. , 2005, Cancer research.
[31] Monilola A. Olayioye,et al. StarD10, a START Domain Protein Overexpressed in Breast Cancer, Functions as a Phospholipid Transfer Protein*[boxs] , 2005, Journal of Biological Chemistry.
[32] C. Tomasetto,et al. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals , 2005, Journal of Cell Science.
[33] S. Okushiba,et al. Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. , 2004, Cancer letters.
[34] D. Lowy,et al. Efficient Intracellular Assembly of Papillomaviral Vectors , 2004, Journal of Virology.
[35] M. Fujii,et al. A PLCδ1‐binding protein, p122/RhoGAP, is localized in caveolin‐enriched membrane domains and regulates caveolin internalization , 2004, Genes to cells : devoted to molecular & cellular mechanisms.
[36] Satoshi Yasuda,et al. Molecular machinery for non-vesicular trafficking of ceramide , 2003, Nature.
[37] Yoon-La Choi,et al. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. , 2003, Lung cancer.
[38] M. Lisanti,et al. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. , 2003, American journal of clinical pathology.
[39] T. Timme,et al. Caveolin‐1 expression is a predictor of recurrence‐free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients , 2003, Cancer.
[40] S. Okushiba,et al. Overexpression of caveolin‐1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage , 2002, Cancer.
[41] M. Lisanti,et al. Caveolin-deficient mice: insights into caveolar function human disease. , 2001, The Journal of clinical investigation.
[42] M. Robinson,et al. Caveolin-1 expression is associated with high-grade bladder cancer. , 2001, Urology.
[43] S. Law,et al. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] D. Lowy,et al. Ras-Specific Exchange Factor GRF: Oligomerization through Its Dbl Homology Domain and Calcium-Dependent Activation of Raf , 1999, Molecular and Cellular Biology.
[45] M. Kattan,et al. Elevated expression of caveolin is associated with prostate and breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] S. Thorgeirsson,et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. , 1998, Cancer research.
[47] J. Glenney. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. , 1989, The Journal of biological chemistry.
[48] M. Sharma,et al. Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma , 2012, Modern Pathology.
[49] P. Lavigne,et al. Mammalian StAR-related lipid transfer (START) domains with specificity for cholesterol: structural conservation and mechanism of reversible binding. , 2010, Sub-cellular biochemistry.
[50] S. Lo,et al. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. , 2008, The international journal of biochemistry & cell biology.